264 related articles for article (PubMed ID: 1361576)
1. Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat.
Simson PE; Johnson KB; Jurevics HA; Criswell HE; Napier TC; Duncan GE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Dec; 263(3):1454-63. PubMed ID: 1361576
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
[TBL] [Abstract][Full Text] [Related]
3. Neonatal 6-OHDA lesions differentially affect striatal D1 and D2 receptors.
Neal BS; Joyce JN
Synapse; 1992 May; 11(1):35-46. PubMed ID: 1351321
[TBL] [Abstract][Full Text] [Related]
4. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats.
Criswell HE; Johnson KB; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756
[TBL] [Abstract][Full Text] [Related]
5. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
Wirtshafter D; Osborn CV
Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
[TBL] [Abstract][Full Text] [Related]
6. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
7. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Van De Witte SV; Groenewegen HJ; Voorn P
Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
[TBL] [Abstract][Full Text] [Related]
8. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Neal-Beliveau BS; Joyce JN
Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
[TBL] [Abstract][Full Text] [Related]
9. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
10. D1 priming enhances both D1- and D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats.
Pollack AE; Thomas LI
Pharmacol Biochem Behav; 2010 Jan; 94(3):346-51. PubMed ID: 19800912
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
[TBL] [Abstract][Full Text] [Related]
12. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y
J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320
[TBL] [Abstract][Full Text] [Related]
13. Postnatal administration of D1 dopamine agonist reverses neonatal dopaminergic lesion-induced changes in striatal enkephalin and substance P systems.
Sivam SP; Cox J
Brain Res; 2006 Feb; 1073-1074():159-63. PubMed ID: 16455064
[TBL] [Abstract][Full Text] [Related]
14. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Cole DG; Growdon JH; DiFiglia M
Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
16. Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa.
Asin KE; Bednarz L; Nikkel A; Perner R
J Pharmacol Exp Ther; 1995 Jun; 273(3):1483-90. PubMed ID: 7791123
[TBL] [Abstract][Full Text] [Related]
17. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
McPherson RJ; Marshall JF
Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
[TBL] [Abstract][Full Text] [Related]
18. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972
[TBL] [Abstract][Full Text] [Related]
20. Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment.
Brus R; Kostrzewa RM; Perry KW; Fuller RW
J Pharmacol Exp Ther; 1994 Jan; 268(1):231-7. PubMed ID: 8301563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
